Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of June 1 to 4, 2021. This …
SARS-CoV-2 RNAemia Infrequent in Blood Donors
Estimated prevalence of SARS-CoV-2 RNA reactive donations 1.16/100,000; no infectivity seen in inoculated permissive cell cultures
Testing for STIs in the U.S. Dropped During Early Pandemic
Low point in testing for chlamydia and gonorrhea seen in early April 2020, raising the possibility of many missed cases
China COVID-19 Vaccine Authorized by the WHO
The World Health Organization (WHO) validated the CoronaVac COVID-19 inactivated vaccine for emergency use on June 1, 2021.
This WHO authorization gives countries, funders, procuring agencies, and communities the assurance that the CoronaVac vaccine meets international standards for safety, efficacy, and manufacturing.
CoronaVac is produced by the Beijing-based pharmaceutical company Sinovac.
Comparative analysis of TOPSIS, VIKOR and COPRAS methods for the COVID-19 Regional Safety Assessment.
COVID-19, which emerged in December 2019, has affected the entire world. Therefore, COVID-19 has been a subject of research in various disciplines, especially in the field of health. One of […]
Clinical evaluation of rapid point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
The RT-qPCR in respiratory specimens is the gold standard for diagnosing acute COVID-19 infections. However, this test takes considerable time before test results become available, thereby delaying patients from being […]
WHO Approves Second Chinese COVID-19 Vaccine
Emergency use authorization based on data showing two doses of Sinovac are about 50 percent effective
Most Severe Effects of PIMS-TS Resolved at Six Months
Findings generally favorable for patients with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2
ASCO: COVID-19 Infections, Deaths Not Up With Breast Cancer Chemo
Risk for death following SARS-CoV-2 infection increased with advanced-stage disease, higher comorbidity, but not receipt of chemotherapy
Drug-Induced Immunosuppression Examined in U.S. Adults
Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine